

Baxter International Inc.
Key Product Line Sales
Period Ending December 31, 2004
(unaudited)

(\$ in millions)	Q4 2004	Q4 2003	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2004	YTD 2003	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$376	\$335	12%	9%	\$1,329	\$1,123	18%	14%
Plasma Proteins ¹	278	295	(6%)	(7%)	1,037	1,005	3%	0%
Antibody Therapy	84	96	(12%)	(15%)	336	311	8%	5%
Transfusion Therapies	150	150	0%	(3%)	550	553	(1%)	(5%)
Other ²	64	60	5%	(8%)	252	277	(9%)	(21%)
Total BioScience	\$952	\$936	2%	(2%)	\$3,504	\$3,269	7%	3%
Medication Delivery								
IV Therapies ³	\$309	\$306	1%	(3%)	\$1,154	\$1,100	5%	0%
Drug Delivery	241	195	24%	23%	789	699	13%	11%
Infusion Systems	236	253	(7%)	(8%)	846	803	5%	3%
Anesthesia	234	229	2%	2%	827	808	2%	2%
Other ⁴	109	114	(4%)	(8%)	431	417	3%	(2%)
Total Medication Delivery⁵	\$1,129	\$1,097	3%	1%	\$4,047	\$3,827	6%	3%
Renal								
PD Therapy	\$382	\$367	4%	1%	\$1,445	\$1,344	8%	3%
HD Therapy	134	126	6%	2%	499	447	12%	6%
Other	4	5	(13%)	0%	14	17	(17%)	(35%)
Total Renal	\$520	\$498	4%	1%	\$1,958	\$1,808	8%	4%
TOTAL BAXTER	\$2,601	\$2,531	3%	0%	\$9,509	\$8,904	7%	3%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

² Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

³ Principally includes intravenous solutions and nutritional products.

⁴ Principally includes oncology and other hospital-distributed products.

⁵ Sales of pain management products, which were previously included in Anesthesia, are now reported in Infusion Systems or Other, depending on the product. All prior sales data has been reclassified to reflect this change.